Phase II Study of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2016
At a glance
- Drugs Muparfostat (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Progen Pharmaceuticals Limited
- 22 Oct 2007 Status changed from in progress to completed.
- 24 Sep 2007 Primary and secondary endpoints not achieved: results reported by Progen Pharmaceuticals.
- 24 Sep 2007 Results data are available.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History